恩替卡韦联合扶正化瘀胶囊治疗失代偿期乙型肝炎肝硬化的临床效果

吕耀

（户县医院，陕西西安，710300）

浏览次数：118次 下载次数：471次

摘要：

目的 分析恩替卡韦联合扶正化瘀胶囊治疗失代偿期乙型肝炎肝硬化的临床效果。方法 选择我院2013年3月至2015年3月收治的失代偿期乙型肝炎肝硬化患者180例为研究对象，按照患者入院顺序分为对照组和联合组，各90例。两组患者均给予临床基本保肝治疗，在此基础上给予对照组患者服用恩替卡韦治疗，联合组患者在对照组用药的基础上联合应用扶正化瘀胶囊治疗。治疗48周后，对两组患者治疗前、后肝纤维化4项指标变化情况及并发症发生率进行比较，并比较两组患者的治疗有效率。结果 治疗后，两组患者在的肝纤维化4项指标均优于治疗前，且联合组的各项指标优于对照组（P<0.05）；联合组患者并发症发生率明显低于对照组（P<0.05)，联合组患者的治疗有效率为98.89%，优于对照组的92.22%（P<0.05）。结论 恩替卡韦联合扶正化瘀胶囊治疗失代偿期乙型肝炎肝硬化，近期治疗的临床效果比较满意，值得临床推广应用。

关键词：恩替卡韦；扶正化瘀胶囊；失代偿期乙型肝炎肝硬化

中图分类号：R512.62文献标志码：A文章编号：2096-1413(2017)07-0054-02

The clinical effect of entecavir combined with Fuzheng Huayu capsule in the treatment of patients with decompensated liver cirrhosis of hepatitis B

LV Yao-qing

(Hu County Hospital, Xi'an 710300, China)

ABSTRACT: Objective To analyze the clinical effect of entecavir combined with Fuzheng Huayu capsule in the treatment of patients with decompensated liver cirrhosis of hepatitis B. Methods One hundred and eighty patients with decompen sated liver cirrhosis of hepatitis B in our hospital from March 2013 to March 2015 were selected as research objects, which were divided into control group and combination group according to the order of admission, with 90 cases in each group.Two groups of patients were all given liver-protecting treatment. On this basis, the patients in the control group were given entecavir treatment, while the patients in combination group were given Fuzheng Huayu capsule on the basis of the control group. The 4 indexes of liver fibrosis, complications and effects of the two groups were compared after 48 weeks treatment. Results After treatment, the indexes of liver fibrosis of patients in the two groups were all better than before treatment, and the indexes of the combination group were better than those of the control group (P<0.05). The complication rate of the combination group was significantly lower than that of the control group (P<0.05). The effective rate of the combination group was 98.89%, which was better than 92.22% of the control group (P<0.05). Conclusion Entecavir combined with Fuzheng Huayu capsule has good clinical effect in the treatment of patients with decompensated liver cirrhosis of hepatitis B, which is worthy of clinical application.

KEYWORDS: entecavir; Fuzheng Huayu capsule; decompensated liver cirrhosis of hepatitis B

参考文献：
[1] 向保云,宋爱军.恩替卡韦联合扶正化瘀胶囊治疗失代偿期乙型肝炎肝硬化疗效观察[J].山东医药,2013,50(41):83-84.
[2] 张永峰.恩替卡韦结合CIK疗法对乙肝病毒感染相关性肝硬化的治疗效果研究[J].中国处方药,2016,14(3):37-38.
[3] 窦宇明,沈桂堂,张丽丽.恩替卡韦联合扶正化瘀胶囊治疗失代偿期乙型肝炎肝硬化21例[J].中西医结合肝病杂志,2012,22(5):302-303.
[4] 邱冰峰,徐骐,徐汤舟,等.拉米夫定对乙型肝炎肝硬化患者肝纤维化状态与血小板参数的影响研究[J].中华医院感染学杂志,2016,26(8):1700-1702.
[5] 张先俊,杨力,胡建国,等.恩替卡韦联合扶正化瘀胶囊治疗失代偿期乙型肝炎肝硬化临床观察[J].中华实用诊断与治疗杂志,2014,24
(12):1217-1219.
[6] 袁成民,杨铂,刘葵花,等.芪冬复肝合剂抗肝纤维化40例临床观察[J].中国中医药科技,2014,21(4):442-443.
[7] 汤勤.扶正化瘀胶囊联合恩替卡韦治疗乙肝后肝硬化活动期疗效观察[J].中外健康文摘,2011,8(44):151-152.
[8] 王守兵,刘星,孟召刚.扶正化瘀胶囊联合恩替卡韦分散片治疗乙型肝炎肝硬化32例疗效观察[J].肝脏,2016,21(1):77-78.